Sanofi Consumer Healthcare India Limited has announced an additional agenda item for its upcoming board meeting, informing stock exchanges about potential dividend considerations for the financial year 2025.

Board Meeting Details

The company has scheduled its Board of Directors meeting for February 25, 2026, which will now include consideration of dividend recommendations alongside the previously announced agenda items.

Regulatory Compliance

The announcement was made in compliance with Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company had previously informed exchanges on February 17, 2026, about the board meeting to consider and approve audited financial statements for the quarter and financial year ended December 31, 2025.

Stock Exchange Communication

Sanofi Consumer Healthcare India Limited has formally notified both major Indian stock exchanges about the expanded meeting agenda:

• BSE Limited: Scrip Code 544250
• National Stock Exchange: Symbol SANOFICONR

The communication was signed by Nikunj Kumar Savaliya, Company Secretary and Compliance Officer (Membership No.: F7048), and submitted on February 20, 2026.

Meeting Agenda

The board meeting will address two key items:

• Consideration and approval of audited financial statements for Q4 and full year ended December 31, 2025
• Potential recommendation of dividend for the financial year ended December 31, 2025

The company has emphasized that dividend consideration remains subject to board discretion during the scheduled meeting.

Sanofi Consumer Healthcare India Limited has announced its financial results for the third quarter, showcasing robust growth across key business segments. The company's performance reflects a strong recovery and expansion in both domestic and export markets.

Financial Highlights

For the quarter ended September 30, Sanofi Consumer Healthcare India reported:

The company's revenue from operations saw a significant increase of 46% year-on-year, reaching ₹2,339.00 million. This growth was driven by a 20% increase in domestic sales and a substantial rise in export sales, which grew by over 1000% from a low base.

Nine-Month Performance

For the nine-month period ended September 30:

The company's revenue for the nine-month period grew by 13% to ₹6,274.00 million, while profit after tax increased by 27% to ₹1,736.00 million.

Key Developments

Sanofi Consumer Healthcare India has successfully relaunched all previously recalled products:

• Depura Adult and Combiflam Suspension were reintroduced earlier in the year
• Allegra Suspension and Depura Kids were relaunched in the September quarter

These relaunch efforts have helped the company re-establish its market presence within the year, contributing to the strong performance in the domestic market.

Management Commentary

Himanshu Bakshi, Managing Director of Sanofi Consumer Healthcare India Limited, commented on the results: "Our third-quarter results reflect the strength of our diversified portfolio driving sustained growth momentum this quarter. The domestic business demonstrates good performance, with exports providing additional impetus to revenue growth. All our voluntarily recalled products have successfully re-established their market presence within the year. Anchored in science and guided by purpose, we remain committed to making self-care simpler, more accessible and more effective for every consumer."

Business Segment and Product Portfolio

Sanofi Consumer Healthcare India operates in the pharmaceutical business segment, with key brands including Allegra, DePURA, Avil, and Combiflam. The company's portfolio encompasses products in Allergy, Digestive Wellness, Pain Care, and Multivitamins categories.

Corporate Updates

On April 30, Sanofi globally closed the sale of a 50% controlling stake of Opal JVco S.a.r.l (Opella group) to Clayton, Dubilier & Rice Fund XII, L.P. Sanofi retains a significant 48.2% stake, while Bpifrance owns a 1.8% stake. As a result, the ultimate parent of Sanofi Consumer Healthcare India is now Opal JVco S.a.r.l instead of Sanofi.

Conclusion

Sanofi Consumer Healthcare India's Q3 results demonstrate the company's resilience and growth potential in the consumer healthcare sector. The successful relaunch of key products, coupled with strong performance in both domestic and export markets, positions the company well for continued growth in the coming quarters.

Investors and stakeholders should note that the quarter and nine-month results are not directly comparable to the previous year due to the demerger and voluntary recall of certain key brand variants in the domestic market. However, the current results indicate a positive trajectory for the company's operations and financial performance.